Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Pushes Personalization With $2.4bn Foundation Buy-Out

Executive Summary

By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.

You may also be interested in...



Roche's New Chief Medical Officer Levi Garraway Brings Deep Cancer Genomics Expertise

CMO Sandra Horning will retire at the end of the year, to be succeeded by Lilly's former senior VP of oncology R&D on 1 October.

Why Roche Oncology Bet Big On Neoantigen-Directed T-Cell Therapy

In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed cellular therapy, after announcing tie-up with Adaptive Biotechnologies.

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

Roche's up and down ESMO is best summed up by the response to data presented on its personalised cancer med entrectinib – good but perhaps not as good as others.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel